 |
|
|
|
|
|
|
Several significant developments related to hydroxyurea (HU) were discussed at the 12th World AIDS Conference in Geneva. A new clinical trial confirmed the capacity of the triple-drug combination
regimen of ddI/d4T/HU to substantially reduce HIV viral loads in naďve patients. Two laboratory studies showed that HU enhances the activity of some of the nucleoside analogs (AZT, 3TC and d4T) through its effect on
another cellular enzyme that is involved in the activation of these drugs. Another laboratory study demonstrated that HU increases the capacity of two new drugs, adefovir and PMPA, to achieve viral suppression, even with
virus known to be multi-drug resistant. Finally, a retrospective study analyzing patient experience found that patients with advanced HIV can benefit from therapies that include HU. All these intriguing reports plus the
general feeling that new therapeutic strategies are needed to overcome the limitations of existing drugs made hydroxyurea a popular subject of conversation at Geneva.
Editor's Note: from GMHC Treatment Issues
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
